Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion type Assertion NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_head.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion description "[A combined prognostic score of tumour budding and CD8(+), FoxP3(+) and CD68(+) distinctly identified patients with low-, moderate- or high-risk colorectal cancers with 5-year survival rates of 75.2% [confidence interval 95% (CI): 66-83], 56.3% (95% CI: 43-68) and 25.2% (95% CI: 14-38), respectively, in MMR-proficient and -deficient cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_provenance.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion evidence source_evidence_literature NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_provenance.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion SIO_000772 22034888 NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_provenance.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion wasDerivedFrom befree-20140225 NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_provenance.
- NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_assertion wasGeneratedBy ECO_0000203 NP552060.RA0BF2zl9_buToFQpPPUtKvq7WV7nTywFXlNQzxDo1mEA130_provenance.